Edwards Lifesciences (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, has received CEO Cancer Gold Standard™ accreditation, recognizing the company’s commitment to reducing cancer risk by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment for their own employees and their covered family members.
Christopher A. Viehbacher chairs the CEO Roundtable on Cancer, a nonprofit organization of cancer-fighting CEOs who created the CEO Cancer Gold Standard™, in collaboration with the National Cancer Institute, many of its designated cancer centers, and leading health non-profit organizations and professionals. Today, more than two million employees and family members are benefiting from the vision and leadership of employers like Edwards Lifesciences who have chosen to become Gold Standard accredited.
“This Gold Standard accreditation is an acknowledgement of the leadership of Michael Mussallem, chairman and CEO of Edwards Lifesciences, and his work on behalf of the health of employees and their families,” said Christopher A. Viehbacher, CEO of Sanofi. “CEO Cancer Gold Standard accreditation is further testament that Edwards Lifesciences’ efforts to improve health begin with improving the health of their own employees.”
The CEO Cancer Gold Standard™ calls for companies to evaluate their health benefits and corporate culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. To earn Gold Standard accreditation, a company must establish programs to reduce cancer risk by discouraging tobacco use; encouraging physical activity; promoting healthy diet and nutrition; detecting cancer at its earliest stages; and providing access to quality care, including participation in clinical trials.